| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that its Board of Directors has authorized the Company's Capital Markets Committee to explore and negotiate non-binding term sheets for potential Digital Asset Treasury (DAT) strategy opportunities. Any such opportunities will be subject to further review and approval by the full Board.
This initiative is part of Enveric's ongoing efforts to enhance shareholder value and support the Company's long-term growth. The Company remains fully committed to advancing its core biotechnology programs and will continue to provide updates as developments occur.
Posted In: ENVB
